{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:25:23Z","timestamp":1786998323529,"version":"build-2736575974"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004784","name":"Novartis Stiftung\u00a0f\u00fcr\u00a0Medizinisch-Biologische Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004784","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["320030_163430"],"award-info":[{"award-number":["320030_163430"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.yebeh.2025.110595","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:06:03Z","timestamp":1753142763000},"page":"110595","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Is the salivary concentration of lamotrigine and levetiracetam associated with clinical outcome?"],"prefix":"10.1016","volume":"171","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8758-9828","authenticated-orcid":false,"given":"Paola","family":"Vassallo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6776-4978","authenticated-orcid":false,"given":"Eva","family":"Choong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"A\u00edcua-Rap\u00fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6659-0790","authenticated-orcid":false,"given":"Camille","family":"Stampfli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7878-172X","authenticated-orcid":false,"given":"Andrea O.","family":"Rossetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0639-5536","authenticated-orcid":false,"given":"Thierry","family":"Buclin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent A.","family":"Decosterd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6862-7083","authenticated-orcid":false,"given":"Jan","family":"Novy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2025.110595_b0005","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/00007691-200306000-00016","article-title":"Therapeutic drug monitoring of the newer antiepileptic drugs","volume":"25","author":"Johannessen","year":"2003","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.yebeh.2025.110595_b0010","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s13318-020-00661-1","article-title":"Feasibility of using oral fluid for therapeutic drug monitoring of antiepileptic drugs","volume":"46","author":"Patrick","year":"2021","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.yebeh.2025.110595_b0015","first-page":"1239","article-title":"Antiepileptic drugs\u2013best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring","volume":"49","author":"Patsalos","year":"2008","journal-title":"ILAE Commission on Therapeutic Strategies Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110595_b0020","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2165\/00003088-199936060-00006","article-title":"Therapeutic drug concentration monitoring using saliva samples","volume":"36","author":"Liu","year":"1999","journal-title":"Focus on anticonvulsants Clin Pharmacokinet"},{"key":"10.1016\/j.yebeh.2025.110595_b0025","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/01.ftd.0000171869.56817.ae","article-title":"Stability of salivary concentrations of the newer antiepileptic drugs in the postal system","volume":"27","author":"Jones","year":"2005","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.yebeh.2025.110595_b0030","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","article-title":"Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update","volume":"40","author":"Patsalos","year":"2018","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.yebeh.2025.110595_b0035","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.seizure.2025.01.013","article-title":"Clinical value of saliva therapeutic drug monitoring of newer antiseizure medications","volume":"125","author":"Choong","year":"2025","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2025.110595_b0040","first-page":"902","article-title":"Monitoring salivary lamotrigine concentrations","volume":"13","author":"Malone","year":"2006","journal-title":"J Clin Neurosci Off J Neurosurg Soc Australas"},{"key":"10.1016\/j.yebeh.2025.110595_b0045","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/FTD.0b013e3180683d55","article-title":"Saliva and serum levetiracetam concentrations in patients with epilepsy","volume":"29","author":"Mecarelli","year":"2007","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.yebeh.2025.110595_b0050","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/00007691-200302000-00009","article-title":"Correlation of levetiracetam concentrations between serum and saliva","volume":"25","author":"Grim","year":"2003","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.yebeh.2025.110595_b0055","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/FTD.0000000000000396","article-title":"Comparison of plasma, saliva, and hair levetiracetam concentrations","volume":"39","author":"Kara\u015b-Ruszczyk","year":"2017","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.yebeh.2025.110595_b0060","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/00007691-200010000-00003","article-title":"Saliva and serum concentration of lamotrigine in patients with epilepsy","volume":"22","author":"Tsiropoulos","year":"2000","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.yebeh.2025.110595_b0065","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1592\/phco.23.15.1550.31957","article-title":"Correlation of lamotrigine concentrations between serum and saliva","volume":"23","author":"Ryan","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.yebeh.2025.110595_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2022.108980","article-title":"Treatment-emergent adverse events and antiseizure medication actual drug load","volume":"137","author":"Pr\u00e9tat","year":"2022","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2025.110595_b0075","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1528-1157.1996.tb00605.x","article-title":"Concentration\u2010effect and concentration\u2010toxicity relations with lamotrigine: a prospective study","volume":"37","author":"Kilpatrick","year":"1996","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110595_b0080","first-page":"152","volume":"46","author":"Goa","year":"1993","journal-title":"Lamotrigine Drugs"},{"key":"10.1016\/j.yebeh.2025.110595_b0085","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.seizure.2009.05.007","article-title":"Levetiracetam in children with refractory epilepsy: lack of correlation between plasma concentration and efficacy","volume":"18","author":"Giroux","year":"2009","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2025.110595_b0090","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.pediatrneurol.2015.01.012","article-title":"Correlation between efficacy of levetiracetam and serum levels among children with refractory epilepsy","volume":"52","author":"Sheinberg","year":"2015","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2025.110595_b0095","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.braindev.2014.11.008","article-title":"The efficacy of levetiracetam for focal seizures and its blood levels in children","volume":"37","author":"Iwasaki","year":"2015","journal-title":"Brain and Development"},{"key":"10.1016\/j.yebeh.2025.110595_b0100","article-title":"Monitoring levetiracetam concentration in saliva during pregnancy is stable and feasible","volume":"30","author":"Li","year":"2024","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.yebeh.2025.110595_b0105","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1212\/01.WNL.0000138424.33979.0C","article-title":"Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy","volume":"63","author":"Hirsch","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2025.110595_b0110","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.yebeh.2017.03.031","article-title":"Lamotrigine serum levels: ceiling effect in people with epilepsy in remission?","volume":"74","author":"D\u2019Anto","year":"2017","journal-title":"Epilepsy Behav EB"},{"key":"10.1016\/j.yebeh.2025.110595_b0115","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/ane.13450","article-title":"Seizure freedom and plasma levels of newer generation antiseizure medications","volume":"144","author":"A\u00edcua-Rap\u00fan","year":"2021","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2025.110595_b0120","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1684\/j.1950-6945.2002.tb00436.x","article-title":"Prospective study on concentration-efficacy and concentration-toxicity: correlations with lamotrigine serum levels","volume":"4","author":"Fr\u00f6scher","year":"2002","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.yebeh.2025.110595_b0125","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/ana.25641","article-title":"Therapeutic drug monitoring of newer antiepileptic drugs: a randomized trial for dosage adjustment","volume":"87","author":"A\u00edcua-Rap\u00fan","year":"2020","journal-title":"Ann Neurol"},{"key":"10.1016\/j.yebeh.2025.110595_b0130","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00007691-199706000-00002","article-title":"The influence of dosage, age, and comedication on steady state plasma lamotrigine concentrations in epileptic children: a prospective study with preliminary assessment of correlations with clinical response","volume":"19","author":"Bartoli","year":"1997","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.yebeh.2025.110595_b0135","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eplepsyres.2006.12.005","article-title":"Prospective assessment of levetiracetam pharmacokinetics during dose escalation in 4- to 12-year-old children with partial-onset seizures on concomitant carbamazepine or valproate","volume":"74","author":"Fountain","year":"2007","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2025.110595_b0140","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies: definition of drug resistant epilepsy","volume":"51","author":"Kwan","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110595_b0145","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.clinbiochem.2019.09.009","article-title":"Comparison of plasma, saliva, and hair lamotrigine concentrations","volume":"74","author":"Kuczynska","year":"2019","journal-title":"Clin Biochem"},{"key":"10.1016\/j.yebeh.2025.110595_b0150","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2165\/00003088-199325060-00003","article-title":"Lamotrigine clinical pharmacokinetics","volume":"25","author":"Rambeck","year":"1993","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.yebeh.2025.110595_b0155","first-page":"211","article-title":"Pharmacokinetics of lamotrigine (Lamictal) in plasma and saliva","author":"Trnavska","year":"1991","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.yebeh.2025.110595_b0160","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1111\/epi.16321","article-title":"When can we trust responders? Serious concerns when using 50% response rate to assess clinical trials","volume":"60","author":"Karoly","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110595_b0165","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/2064027","article-title":"Mechanisms underlying aggressive behavior induced by antiepileptic drugs: focus on topiramate, levetiracetam, and perampanel","author":"Hansen","year":"2018","journal-title":"Behav Neurol"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152550502500335X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152550502500335X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:12:38Z","timestamp":1778616758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152550502500335X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":33,"alternative-id":["S152550502500335X"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2025.110595","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is the salivary concentration of lamotrigine and levetiracetam associated with clinical outcome?","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2025.110595","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110595"}}